Key result
In a real-world observational study in Russia, rivaroxaban provided effective thromboembolism prophylaxis after major joint arthroplasty, with physicians rating efficacy as excellent or good in 97.9% of patients.
Population
2,293 patients undergoing elective major joint arthroplasty in Russia.
Design
Cohort
Follow-up
14 days for knee arthroplasty, 35 days for hip arthroplasty
Authors
Loading...
Supports rivaroxaban for post-arthroplasty VTE prophylaxis in real-world settings; leaves open need for randomized confirmation.
Observational (n=2,293)
Yes
In real-world clinical practice in Russia, rivaroxaban 10 mg daily for VTE prophylaxis after major joint arthroplasty demonstrated high efficacy, good tolerability, and a low rate of adverse events.
Zagorodniy et al. (2015) conducted an observational in Prevention of thromboembolism after major joints arthroplasty (n=2,293). Rivaroxaban was evaluated on Physician assessment of drug efficacy as excellent or good. In a real-world observational study in Russia, rivaroxaban provided effective thromboembolism prophylaxis after major joint arthroplasty, with physicians rating efficacy as excellent or good in 97.9% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: